The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Signaling effectors underlying pathologic growth and remodeling of the heart
Open accessAbstract
Cardiovascular disease is the number one cause of mortality in the Western world.The heart responds to many cardiopathological conditions with hypertrophic growth by enlarging individual myocytes to augment cardiac pump function and decrease ventricular wall tension.Initially, such cardiac hypertrophic growth is often compensatory, but as time progresses these changes become maladaptive.Cardiac hypertrophy is the strongest predictor for the development of heart failure, arrhythmia, and sudden death.Here we discuss therapeutic avenues emerging from molecular and genetic studies of cardiovascular disease in animal models.The majority of these are based on intracellular signaling pathways considered central to pathologic cardiac remodeling and hypertrophy, which then leads to heart failure.We focus our discussion on selected therapeutic targets that have more recently emerged and have a tangible translational potential given the available pharmacologic agents that could be readily evaluated in human clinical trials.β-Adrenergic receptor signaling and associated kinases in cardiac hypertrophy and remodeling Inhibition of β-adrenergic receptor signaling is perhaps the most effective and frequently employed therapy in addressing negative Conflict of interest:The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Wall stress and patterns of hypertrophy in the human left ventricle.
Grossman, W., Jones, D., & McLaurin, L. P. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108079 · Cited by 2,403
beta Blockade after myocardial infarction: systematic review and meta regression analysis
Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J. (1999) · BMJ · doi:10.1136/bmj.318.7200.1730 · Cited by 1,509 · cited 1×
“…signaling pathways that have emerged more recently from mechanistic and genetic studies in animal models of cardiac remodeling that offer new treatment opportunities. cardiac remodeling associated with hypertension, postmyocardial infarction remodeling, or early stages of heart failure (27–30).”
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430 · cited 1×
“Additional side branches in this cascade include ERK5 and its upstream activator MEK5, as well as ERK3/4, although the upstream regulatory kinases for these effectors are not well characterized (94, 95).”
Sensitivity of CaM Kinase II to the Frequency of Ca 2+ Oscillations
De Koninck, P., & Schulman, H. (1998) · Science · doi:10.1126/science.279.5348.227 · Cited by 1,269
Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61219-1 · Cited by 262
Calcium channel blockers in heart failure
Elkayam, U. (1998) · Cardiology · doi:10.1159/000047278 · Cited by 69
Cited by
Molecular basis of physiological heart growth: fundamental concepts and new players
Maillet, M., van Berlo, J. H., & Molkentin, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3495 · Cited by 536
Self-citationBET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406
Cardiac Resident Macrophages Prevent Fibrosis and Stimulate Angiogenesis
Revelo, X. S., Parthiban, P., Chen, C., Barrow, F., Fredrickson, G., Wang, H., Yücel, D., Herman, A., & van Berlo, J. H. (2021) · Circulation Research · doi:10.1161/circresaha.121.319737 · Cited by 298
Self-citationDuan, Q., McMahon, S., Anand, P., Shah, H., Thomas, S., Salunga, H. T., Huang, Y., Zhang, R., Sahadevan, A., Lemieux, M. E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5084 · Cited by 262
Cardiac Nonmyocytes in the Hub of Cardiac Hypertrophy
Kamo, T., Akazawa, H., & Komuro, I. (2015) · Circulation Research · doi:10.1161/circresaha.117.305349 · Cited by 171
Heart failure: when form fails to follow function
Katz, A. M., & Rolett, E. L. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv548 · Cited by 141
Tomo-Seq identifies SOX9 as a key regulator of cardiac fibrosis during ischemic injury
Lacraz, G. P. A., Junker, J. P., Gladka, M. M., Molenaar, B., Scholman, K. T., Vigil-Garcia, M., Versteeg, D., de Ruiter, H., Vermunt, M. W., Creyghton, M. P., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027832 · Cited by 111
Regulatory Actions of Estrogen Receptor Signaling in the Cardiovascular System
Ueda, K., Adachi, Y., Liu, P., Fukuma, N., & Takimoto, E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00909 · Cited by 60
Padmanabhan, A., Alexanian, M., Linares-Saldana, R., González-Terán, B., Andreoletti, G., Huang, Y., Connolly, A. J., Kim, W., Hsu, A., Duan, Q., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047753 · Cited by 60
Metadata
- Authors
- van Berlo, J. H., Maillet, M., & Molkentin, J. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-01-02
- Volume
- 123
- Issue
- 1
- Pages
- 37-45
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2167407855
- Cited by
- 445
- References
- 8
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
